ProCE Banner Activity

BTK Inhibitor Therapy for CLL: An International Perspective

Clinical Thought

In this commentary, an international expert discusses contemporary use of BTK inhibitor therapy for CLL.

Released: March 28, 2023

Expiration: March 27, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an educational grant from

AstraZeneca

Faculty Disclosure

Stephan Stilgenbauer: consultant/advisor/speaker: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem; researcher: AbbVie, Acerta, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Hoffmann-La Roche, Infinity, Janssen, Novartis, Sunesis, Verastem.